¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѺñ´¢±âÁ¾¾çÇÐȸ The 22nd KUOS Multidisciplinary Conference(2ÀÏÂ÷) : 2024-03-23

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇѺñ´¢±âÁ¾¾çÇÐȸ The 22nd KUOS Multidisciplinary Conference(2ÀÏÂ÷) : 2024-03-23
±³À°ÀÏÀÚ : 2024-03-23
±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ

±³À°ÁÖÁ¦ : The 22nd KUOS Multidisciplinary Conference(2ÀÏÂ÷)

ÁÖÃÖ±â°ü : ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ
´ã´çÀÚ : ±èÀºÁÖ
¿¬¶ôó : 02-704-8574  

À̸ÞÀÏ : app@app2010.com

±³À°Á¾·ù : ºñ´¢ÀÇÇаú

Âü¼®¿¹»óÀÎ : 200¸í
Èñ¸ÁÆòÁ¡ : 4Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 4 ½Ã°£ 20ºÐ

¼¼ºÎ¼ö°­·á : 30,000¿ø  

ºñ°í Àü¹®ÀÇ: 30,000¿ø / Àü°øÀÇ, ±ºÀÇ°ü, °£È£»ç: 20,000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 09:00~09:20 MRI and renal tumors À̽¼ö(¿¬¼¼ÀÇ´ë ¿µ»óÀÇÇаú)

±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 09:20~09:40 Contrast-enhanced US and renal tumors ±è»óÀ±(¼­¿ïÀÇ´ë ¿µ»óÀÇÇаú)

±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 09:40~10:00 (±¸¿¬) 1. Optimal treatment strategy for patients with oligometastatic RCC ±Ç¹Î¼®(¾ÆÁÖÀÇ´ë Á¾¾ç³»°ú)

±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 10:00~10:20 (±¸¿¬) 2. Role of adjuvant pembrolizumab after metastatectomy in oligometastatic RCC: based on updated results of KN564 trial ¼Û丰(¿ï»êÀÇ´ë ºñ´¢ÀÇÇаú)

ÈÞ½Ä 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 10:20~10:40 Break ( )

±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 10:40~11:10 Prostate Cancer Genome Profiling – The Need for Global Inclusion Vanessa Hayes(University of Sydney)

±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 11:10~11:23 (±¸¿¬) 1. Neoadjuvant treatment for advanced prostate cancer ¹Ú¼º¿ì(ºÎ»êÀÇ´ë ºñ´¢ÀÇÇаú)

±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 11:23~11:36 (±¸¿¬) 2. Genetic testing for advanced prostate cancer ¿ÀÁÖÇö(°¡Å縯ÀÇ´ë ÇÙÀÇÇаú)

±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 11:36~11:50 (±¸¿¬) 3. PSMA targeted therapy for mCRPC ÀÓÀ缺(Ãæ³²ÀÇ´ë ºñ´¢ÀÇÇаú)

±âŸ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 11:50~12:00 Photo ( )

½Ä»ç 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 12:00~13:40 Lunch ( )

±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 13:40~14:10 Antibody-Drug Conjugates (ADC) °³¹ßÀÇ ÇöÀç¿Í ¹Ì·¡ Á¤Ã¶¿õ(·¹°íÄ·¹ÙÀÌ¿À ADC ¿¬±¸¼ÒÀå)

ÈÞ½Ä 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 14:10~14:30 Break ( )

±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 14:30~14:50 Urothelial carcinoma: 2022 5th WHO classification ¹®°æö(¼­¿ïÀÇ´ë º´¸®°ú)

±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 14:50~15:10 What¡¯s new about kidney tumors? ±è¿µ¾Æ(¼­¿ïÀÇ´ë º´¸®°ú)

±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:10~15:20 (±¸¿¬) 1. What is the optimal regimen and schedule for NAC in MIBC ±èÀÎÈ£(°¡Å縯ÀÇ´ë Á¾¾ç³»°ú)

±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:20~15:30 (±¸¿¬) 2. Is post NAC clinical assessment truly necessary, and if so, how should it be conducted ¹Ú½Âö(¿ø±¤ÀÇ´ë ºñ´¢ÀÇÇаú)

±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:30~15:40 (±¸¿¬) 3. Should radical cystectomy be performned for MIBC patients who achieve a cT0 Status after NAC ¼ºÇöȯ(¼º±Õ°üÀÇ´ë ºñ´¢ÀÇÇаú)

±³À°½Ã°£ 03¿ù 23ÀÏ ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:40~15:50 (±¸¿¬) 4. What is the evidence supporting NAC for bladder preservation in MIBC ÀÌ»ó¿í(¼øõÇâÀÇ´ë ºñ´¢ÀÇÇаú)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ The 22nd KUOS Multidisciplinary Conference(2ÀÏÂ÷) : 2024-03-23""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2024³â ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ÀüºÏÁöȸ ¿¬¼ö°­Á : 2024-03-23
´ÙÀ½±Û ´ëÇÑâ»óÇÐȸ The Wound Meeting 2024 Seoul - 1ÀÏÂ÷ : 2024-03-22
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20925 ÀüºÏ Á¦ 53Â÷ ´ëÇѳëÀκ´ÇÐȸ È£³²Áöȸ ÇмúÁý´äȸ : 2024-07-27 0 15 2024-05-28
20924 ¼­¿ï 2024 Á¦27ȸ ´ëÇѾȸ鼺ÇüÀç°ÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-21 0 18 2024-05-28
20923 °æ±â 2024³â ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¾ö : 2024-07-21 0 13 2024-05-28
20922 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(2ÀÏÂ÷) : 2024-07-20 0 8 2024-05-28
20921 ¼­¿ï Á¦33Â÷ ´ç´¢º´ ¿¬±¸ ÇÏ°è¿öÅ©¼¥ : 2024-07-20 0 9 2024-05-28
20920 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GU Cancers 2024 : 2024-07-19 0 14 2024-05-28
20919 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(1ÀÏÂ÷) : 2024-07-19 0 4 2024-05-28
20918 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-07-14 0 4 2024-05-28
20917 °æºÏ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ ¿µ³² ¿¬¼ö°­Á : 2024-07-14 0 5 2024-05-28
20916 °æ±â ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-13 0 7 2024-05-28
20915 °æ±â 2024³â ÀÇÁ¤ºÎÀ»Áö´ëÇб³º´¿ø Á¦1ȸ ½Å°æ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2024-07-13 0 6 2024-05-28
20914 ºÎ»ê Á¦6ȸ ºÎ»ê¼º¸ðº´¿ø ¼Ò¾Æû¼Ò³â°ú ½ÉÆ÷Áö¾ö : 2024-07-13 0 4 2024-05-28
20913 ¼­¿ï 2024 ´ëÇѽŰ泻ºÐºñ¿¬±¸È¸ ¿¬¼ö°­Á : 2024-07-13 0 7 2024-05-28
20912 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦3Â÷¿¬¼ö±³À° : 2024-07-11 0 6 2024-05-28
20911 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-08 0 8 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷